Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.

Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, Califf RM.

Circulation. 2006 Jan 17;113(2):203-12. Epub 2006 Jan 9.

3.
4.
5.
6.

The use of medications in the secondary prevention of coronary artery disease in the Asian region.

Dalal J, Low LP, Van Phuoc D, Abdul Rahman AR, Reyes E, Ann Soenarta A, Tomlinson B.

Curr Med Res Opin. 2015 Mar;31(3):423-33. doi: 10.1185/03007995.2015.1010035. Epub 2015 Feb 11. Review.

PMID:
25629795
7.
8.

Interaction between angiotensin-converting enzyme inhibitors and aspirin: a review.

Meune C, Mahe I, Mourad JJ, Simoneau G, Knellwolf AL, Bergmann JF, Caulin C.

Eur J Clin Pharmacol. 2000 Dec;56(9-10):609-20. Review.

PMID:
11214765
9.

[Risk management of coronary artery disease--pharmacological therapy].

Hofmann T.

Wien Med Wochenschr. 2004 Jun;154(11-12):266-81. Review. German.

PMID:
15287703
10.

Long-term anticoagulant therapy in patients with coronary artery disease.

Husted SE, Ziegler BK, Kher A.

Eur Heart J. 2006 Apr;27(8):913-9. Epub 2006 Jan 9. Review.

11.

Benefits of optimising drug treatment in home-dwelling elderly patients with coronary artery disease.

Strandberg T, Pitkala K, Tilvis R.

Drugs Aging. 2003;20(8):585-95. Review.

PMID:
12795626
12.

[Pharmacological strategies in prevention of vascular injury].

Fernández Jiménez P, Solera Santos J.

Rev Clin Esp. 2005 Aug;205(8):395-7. Review. Spanish.

PMID:
16143089
13.

Prevention or reversal of atherosclerosis: review of current evidence.

Blankenhorn DH.

Am J Cardiol. 1989 May 2;63(16):38H-41H. Review.

PMID:
2650523
Items per page

Supplemental Content

Write to the Help Desk